Pharmaceutical

Influenza (quadrivalent) vaccine by Pfizer for Influenzavirus B Infections: Likelihood of Approval

Influenza (quadrivalent) vaccine is under clinical development by Pfizer and currently in Phase III for Influenzavirus B Infections.

May 17, 2024 - 04:00
Influenza (quadrivalent) vaccine is under clinical development by Pfizer and currently in Phase III for Influenzavirus B Infections.
Read the original article

Tags:

Previous Article

Opzelura by Incyte for Graft Versus Host Disease (GVHD): Likelihood of Approval

Next Article

Influenza (quadrivalent) vaccine by Pfizer for Influenzavirus A Infections: Like...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharma loses a key battle over a state law concerning 340B pharmacies

STAT+: Pharma loses a key battle over a state law conce...

Mar 13, 2024

A letter from the executive editor: STAT’s investigation into a UnitedHealth algorithm

A letter from the executive editor: STAT’s investigatio...

Nov 15, 2023

Danam signs merger agreement with Artemis

Danam signs merger agreement with Artemis

Aug 8, 2023